CS-1103

Phase 2Small molecule

CClear Scientific, Inc.

CS-1103 is one of 5 small molecule programs targeting Fentanyl. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

FentanylRecruiting

Methamphetamine IntoxicationRecruiting

FentanylPhase 2

Recruiting

Methamphetamine IntoxicationPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Fentanyl

#DrugCompanyPhaseTrials

Duragesic

CCephalon

Phase 2

19 2

Naloxone Hydrochloride

PPurdue Pharma LP

Phase 2

1 3

Sterile Saline

CClear Scientific, Inc.

Phase 2

1 4

CS-1103

CClear Scientific, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Methamphetamine Intoxication

NCT06721494

Q4 2026

Phase 2Recruiting

Fentanyl

NCT07459166

Clinical

Trials by Indication[1]

ART1 trial

A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants

Completed·CClear Scientific, Inc.·Phase 1·NCT06316973·32 enrolled

Methamphetamine Intoxication1 trial

A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine

Recruiting·CClear Scientific, Inc.·Phase 2·NCT06721494·40 enrolled

Fentanyl1 trial

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Dose of Intravenous CS 1103 Following a Single Intravenous Dose of Fentanyl in Healthy Subjects With Naloxone Blockade

Recruiting·CClear Scientific, Inc.·Phase 2·NCT07459166·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for CS-1103. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CS-1103 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CS-1103. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Clear Scientific, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CClear Scientific, Inc.

CS-1103

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

ART1 trial

Methamphetamine Intoxication1 trial

Fentanyl1 trial

References

Drug Info

Quick Facts

Related News